MF59: a safe and potent adjuvant for human use

Immunopotentiators in Modern Vaccines

Volumn , Issue , 2005, Pages 149-159

  Podda, Audino ^a   Giudice, Giuseppe Del ^a   O'Hagan, Derek T ^b  

^a CHIRON VACCINES   (Italy)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85148814452     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088403-2/50010-1     Document Type: Chapter

References (47)

1. AIDS (2001) Vaccine Evaluation Group 022 Protocol Team: cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120. J. Infect. Dis. 183 563-570.
2. A.C. Allison and N.E. Byars (1986) An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. J. Immunol. Methods 95 157-168.
3. A. Banzhoff, P. Nacci and A. Podda (2003) A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 49 177-184.
4. D.I. Bernstein, M.R. Schleiss, K. Berencsi, E. Gonczol, M. Dickey, P. Khoury, M. Cadoz, C. Meric, J. Zahradnik, A.M. Duliege and S. Plotkin (2002) Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults. J. Infect. Dis. 185 685-690. Epub 2002 Feb 2006
5. W. Borkowsky, D. Wara, T. Fenton, J. McNamara, M. Kang, L. Mofenson, E. McFarland, C. Cunningham, A.M. Duliege, D. Francis, Y. Bryson, S. Burchett, S.A. Spector, L.M. Frenkel, S. Starr, R. Van Dyke and E. Jimenez (2000) Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 Collaborators. J. Infect. Dis. 181 890-896.
6. R.L. Burke, C. Goldbeck, P. Ng, L. Stanberry, G. Ott and G. Van Nest (1994) The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine. J. Infect. Dis. 170 1110-1119.
7. S. Cherpelis, I. Srivastava, A. Gettie, X. Jin, D.D. Ho, S.W. Barnett and L. Stamatatos (2001) DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques. J. Virol. 75 1547-1550.
8. L. Corey, A.G. Langenberg, R. Ashley, R.E. Sekulovich, A.E. Izu, J.M. Douglas Jr., H.H. Handsfield, T. Warren, L. Marr, S. Tyring, R. DiCarlo, A.A. Adimora, P. Leone, C.L. Dekker, R.L. Burke, W.P. Leong and S.E. Straus (1999) Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group [see comments]. JAMA 282 331-340.
9. C.K. Cunningham, D.W. Wara, M. Kang, T. Fenton, E. Hawkins, J. Mcnamara, L. Mofenson, A.M. Duliege, D. Francis, E.J. McFarland and W. Borkowsky (2001) Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women. Clin. Infect. Dis. 32 801-807.
10. S. De Donato, D. Granoff, M. Minutello, G. Lecchi, M. Faccini, M. Agnello, F. Senatore, P. Verweij, B. Fritzell, A. Podda, A. Sjolander, J.C. Cox and I.G. Barr (1999) Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly; ISCOMs: an adjuvant with multiple functions. Vaccine 17 3094-3101.
11. M. Dupuis, T.J. Murphy, D. Higgins, M. Ugozzoli, G. Van Nest, G. Ott and D.M. McDonald (1998) Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell. Immunol. 186 18-27.
12. M. Dupuis, D.M. McDonald and G. Ott (1999) Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice. Vaccine 18 434-439.
13. M. Dupuis, K. Denis-Mize, A. LaBarbara, W. Peters, I.F. Charo, D.M. McDonald and G. Ott (2001) Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis. Eur. J. Immunol. 31 2910-2918.
14. F. Ellouz, A. Adam, R. Ciorbaru and E. Lederer (1974) Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem. Biophys. Res. Commun. 59 1317-1325.
15. S. Frey, G. Poland, S. Percell and A. Podda (2003) Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults. Vaccine 21 4234-4237.
16. A. Glenny, C. Pope, H. Waddington and U. Falacce (1926) The antigenic value of toxoid precipitated by potassium alum. J. Pathol. Bacteriol. 29 31-40.
17. D.M. Granoff, Y.E. McHugh, H.V. Raff, A.S. Mokatrin and G.A. Van Nest (1997) MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM197 conjugate vaccine. Infect. Immun. 65 1710-1715.
18. T.C. Heineman, M.L. Clements-Mann, G.A. Poland, R.M. Jacobson, A.E. Izu, D. Sakamoto, J. Eiden, G.A. Van Nest and H.H. Hsu (1999) A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine 17 2769-2778.
19. J.O. Kahn, F. Sinangil, J. Baenziger, N. Murcar, D. Wynne, R.L. Coleman, K.S. Steimer, C.L. Dekker and D. Chernoff (1994) Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. J. Infect. Dis. 170 1288-1291.
20. M.C. Keefer, B.S. Graham, M.J. McElrath, T.J. Matthews, D.M. Stablein, L. Corey, P.F. Wright, D. Lawrence, P.E. Fast, K. Weinhold, R.H. Hsieh, D. Chernoff, C. Dekker and R. Dolin (1996) Safety and immunogenicity of Env 2–3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. AIDS Res. Hum. Retroviruses 12 683-693.
21. W. Keitel, R. Couch, N. Bond, S. Adair, G. Van Nest and C. Dekker (1993) Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant. Vaccine 11 909-913.
22. A.G. Langenberg, R.L. Burke, S.F. Adair, R. Sekulovich, M. Tigges, C.L. Dekker and L. Corey (1995) A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected] [published erratum appears in Ann. Intern. Med. (1995) 123, 395]. Ann. Intern. Med. 122 889-898.
23. G.R. Matyas, N.M. Wassef, M. Rao and C.R. Alving (2000) Induction and detection of antibodies to squalene. J. Immunol. Methods 245 1-14.
24. G.R. Matyas, M. Rao, P.R. Pittman, R. Burge, I.E. Robbins, N.M. Wassef, B. Thivierge and C.R. Alving (2004) Detection of antibodies to squalene: III. Naturally occurring antibodies to squalene in humans and mice. J. Immunol. Methods 286 47-67.
25. E.J. McFarland, W. Borkowsky, T. Fenton, D. Wara, J. McNamara, P. Samson, M. Kang, L. Mofenson, C. Cunningham, A.M. Duliege, F. Sinangil, S.A. Spector, E. Jimenez, Y. Bryson, S. Burchett, L.M. Frenkel, R. Yogev, F. Gigliotti, K. Luzuriaga and R.A. Livingston (2001) Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine. J. Infect. Dis. 184 1331-1335. Epub 2001 Oct 1310
26. D.K. Mitchell, S.J. Holmes, R.L. Burke, A.M. Duliege and S.P. Adler (2002) Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. Pediatr. Infect. Dis. J. 21 133-138.
27. K.G. Nicholson, A.E. Colegate, A. Podda, I. Stephenson, J. Wood, E. Ypma and M.C. Zambon (2001) Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357 1937-1943.
28. D.T. O'Hagan and N.M. Valiante (2003) Recent advances in the discovery and delivery of vaccine adjuvants. Nature Rev. Drug Discov. 2 727-735.
29. D.T. O'Hagan, M. Ugozzoli, J. Barackman, M. Singh, J. Kazzaz, K. Higgins, T.C. VanCott and G. Ott (2000) Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1. Vaccine 18 1793-1801.
30. D.T. O'Hagan, M. Singh, J. Kazzaz, M. Ugozzoli, M. Briones, J. Donnelly and G. Ott (2002) Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen. Vaccine 20 3389-3398.
31. D.T. O'Hagan, M. Singh, C. Dong, M. Ugozzoli, K. Berger, E. Glazer, M. Selby, M. Wininger, P. Ng, K. Crawford, X. Paliard, S. Coates and M. Houghton (2004) Cationic microparticles are a potent delivery system for a HCV DNA vaccine. Vaccine 23 672-680.
32. G. Ott, G.L. Barchfeld and G. Van Nest (1995) Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Vaccine 13 1557-1562.
33. G. Ott, R. Radhakrishnan, J.-H. Fang and M. Hora (2000) D. O'Hagan,(Eds) Vaccine Adjuvants: Preparation Methods And Research Protocols Totowa, NJ: Humana Press 211-228.
34. G. Otten, M. Schaefer, B. Doe, H. Liu, I. Srivastava, J. zur Megede, D. O'Hagan, J. Donnelly, G. Widera, D. Rabussay, M.G. Lewis, S. Barnett and J.B. Ulmer (2004) Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 22 2489-2493.
35. G.R. Otten, M. Schaefer, C. Greer, M. Calderon-Cacia, D. Coit, J. Kazzaz, A. Medina-Selby, M. Selby, M. Singh, M. Ugozzoli, J. zur Megede, S. Barnett, D. O'Hagan, J. Donnelly and J.B. Ulmer (2003) Induction of broad and potent anti-HIV immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed PLG microparticles. J. Virol. 77 6087-6092.
36. A. Podda (2001) The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 19 2673-2680.
37. A. Podda and G. Del Giudice (2003) MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev. Vaccines 2 197-203.
38. A. Podda and G. Del Giudice (2004) M. Levine, J.B. Kaper, R. Rappuoli, M. Liu, M.F. Good,(Eds) New Generation Vaccines New York: Marcel Dekker 225-235.
39. G. Ramon (1925) Sur l'augmentation anormale de l'antitoxine chez les chevaux producteurs de serum antidiptherique. Bull. Soc. Centr. Med. Vet. 101 227-234.
40. I. Stephenson, K.G. Nicholson, A. Colegate, A. Podda, J. Wood, E. Ypma and M. Zambon (2003) Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 21 1687-1693.
41. I. Stephenson, K.G. Nicholson, R. Bugarini, A. Podda, J. Wood, M. Zambon and J. Katz (2005) Cross reactivity to highly pathogenic avian influenza H5N1 viruses following vaccination with non-adjuvanted and MF-59-adjuvanted influezna A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J. Infect. Dis. 191 1210-1215.
42. M.A. Strassburg, S. Greenland, F.J. Sorvillo, L.E. Lieb and L.A. Habel (1986) Influenza in the elderly: report of an outbreak and a review of vaccine effectiveness reports. Vaccine 4 38-44.
43. P. Traquina, M. Morandi, M. Contorni and G. Van Nest (1996) MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. J. Infect. Dis. 174 1168-1175.
44. A. Uehara, S. Yang, Y. Fujimoto, K. Fukase, S. Kusumoto, K. Shibata, S. Sugawara and H. Takada (2005) Muramyldipeptide and diaminopimelic acid-containing desmuramylpeptides in combination with chemically synthesized Toll-like receptor agonists synergistically induced production of interleukin-8 in a NOD2- and NOD1-dependent manner, respectively, in human monocytic cells in culture. Cell Microbiol. 7 53-61.
45. J.P. Valensi, J.R. Carlson and G.A. Van Nest (1994) Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. J. Immunol. 153 4029-4039.
46. V.F. Vidal, N. Casteran, C.J. Riendeau, H. Kornfeld, E.C. Darcissac, A. Capron and G.M. Bahr (2001) Macrophage stimulation with Murabutide, an HIV-suppressive muramyl peptide derivative, selectively activates extracellular signal-regulated kinases 1 and 2, C/EBPbeta and STAT1: role of CD14 and Toll-like receptors 2 and 4. Eur. J. Immunol. 31 1962-1971.
47. J. Wintsch, C.L. Chaignat, D.G. Braun, M. Jeannet, H. Stalder, S. Abrignani, D. Montagna, F. Clavijo, P. Moret, J.M. Dayer, et al. (1991) Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccine. J. Infect. Dis. 163 219-225.